Jibeier released its 2026 interim report. The company's total operating revenue was 490 million yuan, and net profit attributable to the parent was 99.2384 million yuan, down 33.54% from the same period last year. Net cash inflow from operating activities was 133 million yuan, down 15.18% year-on-year. The company's asset-liability ratio was 8.98%, gross margin was 90.08%, and diluted earnings per share was 0.50 yuan, down 33.33% year-on-year. The number of shareholders was 7,516, and the top ten shareholders held 72.26% of the total share capital.
Jiangsu Jibeier Pharmaceutical Co LtdNet profit down 33.54% year-on-year in interim report.
